HK1211888A1 - Tripterygium wilfordii extracts to overcome chemotherapy resistance - Google Patents

Tripterygium wilfordii extracts to overcome chemotherapy resistance Download PDF

Info

Publication number
HK1211888A1
HK1211888A1 HK15112784.8A HK15112784A HK1211888A1 HK 1211888 A1 HK1211888 A1 HK 1211888A1 HK 15112784 A HK15112784 A HK 15112784A HK 1211888 A1 HK1211888 A1 HK 1211888A1
Authority
HK
Hong Kong
Prior art keywords
cancer
wilfordii
organic solvent
treatment
chemotherapeutic
Prior art date
Application number
HK15112784.8A
Other languages
English (en)
Chinese (zh)
Inventor
Moses Sing Sum Chow
Ying Huang
Jinghua Jeffrey Wang
Ranadheer RAVULA
Zhi Jun WANG
Original Assignee
Western University Of Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Western University Of Health Sciences filed Critical Western University Of Health Sciences
Publication of HK1211888A1 publication Critical patent/HK1211888A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15112784.8A 2012-08-19 2013-08-19 Tripterygium wilfordii extracts to overcome chemotherapy resistance HK1211888A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261684792P 2012-08-19 2012-08-19
US61/684,792 2012-08-19
PCT/US2013/055602 WO2014031543A1 (en) 2012-08-19 2013-08-19 Tripterygium wilfordii extracts to overcome chemotherapy resistance

Publications (1)

Publication Number Publication Date
HK1211888A1 true HK1211888A1 (en) 2016-06-03

Family

ID=50150329

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15112587.7A HK1212270A1 (en) 2012-08-19 2013-08-19 Tripterygium wilfordii extracts to overcome chemotherapy resistance
HK15112784.8A HK1211888A1 (en) 2012-08-19 2013-08-19 Tripterygium wilfordii extracts to overcome chemotherapy resistance

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15112587.7A HK1212270A1 (en) 2012-08-19 2013-08-19 Tripterygium wilfordii extracts to overcome chemotherapy resistance

Country Status (9)

Country Link
US (1) US10149876B2 (enExample)
EP (1) EP2888011A4 (enExample)
JP (1) JP6367801B2 (enExample)
CN (1) CN104797296B (enExample)
AU (2) AU2013306058A1 (enExample)
CA (1) CA2880575C (enExample)
HK (2) HK1212270A1 (enExample)
IN (1) IN2015DN01496A (enExample)
WO (1) WO2014031543A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201523B2 (en) 2013-09-13 2019-02-12 Western University Of Health Sciences Use of wilforlide A for overcoming chemotherapy resistance
CN111909119B (zh) * 2020-08-25 2023-06-16 上海诗丹德标准技术服务有限公司 雷公藤来源化合物及其应用和制备方法、药物组合物、杀虫剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013627A1 (en) 1990-03-14 1991-09-19 The Board Of Regents, The University Of Texas System Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
US20060094775A1 (en) 2003-02-27 2006-05-04 Teruo Nishida Remedy for corneal ulcer
CN102443039B (zh) 2010-10-14 2013-11-13 中国科学院上海药物研究所 N-取代氨基苯基-14β-氨甲基表雷公藤内酯醇衍生物及其制备方法和用途

Also Published As

Publication number Publication date
AU2018200709B2 (en) 2019-10-24
HK1212270A1 (en) 2016-06-10
EP2888011A1 (en) 2015-07-01
CN104797296A (zh) 2015-07-22
IN2015DN01496A (enExample) 2015-07-03
CN104797296B (zh) 2019-12-17
AU2013306058A1 (en) 2015-02-19
JP2015529664A (ja) 2015-10-08
AU2018200709A1 (en) 2018-02-22
WO2014031543A1 (en) 2014-02-27
EP2888011A4 (en) 2016-01-27
US20150238553A1 (en) 2015-08-27
CA2880575C (en) 2023-07-11
CA2880575A1 (en) 2014-02-27
JP6367801B2 (ja) 2018-08-01
US10149876B2 (en) 2018-12-11

Similar Documents

Publication Publication Date Title
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
HK1247093A1 (zh) 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法
HK1247092A1 (zh) 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法
WO2007084670A3 (en) Specific therapy using integrin ligands for treating cancer
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
WO2008087025A3 (en) Specific therapy and medicament using integrin ligands for treating cancer
WO2016025635A3 (en) Combination therapy for treating cancer
EP4140487A8 (en) Combination therapy for treating cancer
RU2016112608A (ru) Лечение рака комбинацией плинабулина и таксана
WO2016207090A3 (en) Targeted conjugates of ksp inhibitors
WO2011017534A3 (en) Treatment of prostate cancer
CL2014002097A1 (es) Compuestos derivados de tetrahidro-quinazolinona, inhibidores de tank y parp-1; proceso de preparacion; medicamentos; kit farmaceutico; uso en el tratamiento y/o la prevencion de cancer, esclerosis multiple, enfermedades cardiovasculares, lesion del sistema nervioso central.
WO2016054480A3 (en) Venous access catheters and methods for portal venous system catheterization
HK1223304A1 (zh) 包含二甲双胍和二氢槲皮素的药物组合及其用於治疗癌症的用途
ZA202302155B (en) Interferon-based cancer treatment method and pharmaceutical composition
WO2016127168A3 (en) Mebendazole polymorph for treatment and prevention of tumors
PH12016501527A1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
MX2015015434A (es) Corroles dirigidas para toxicidad tumoral y rm.
WO2008089070A3 (en) Combination therapy for the treatment of cancer
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
HK1211888A1 (en) Tripterygium wilfordii extracts to overcome chemotherapy resistance
WO2017013490A3 (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제